Core Insights - Century Therapeutics is advancing its pipeline of induced pluripotent stem cell (iPSC)-derived therapies targeting autoimmune diseases and cancer, with a focus on type 1 diabetes and a strong financial position following a $135 million private placement [2][10] Financial Performance - For the year ended December 31, 2025, collaboration revenue increased significantly to $109.2 million from $6.6 million in 2024, reflecting successful partnerships [10] - Research and development (R&D) expenses decreased to $95.7 million from $107.2 million in 2024, attributed to reduced personnel and manufacturing costs [10] - General and administrative (G&A) expenses also fell to $24.0 million from $33.2 million in 2024, primarily due to lower legal fees and other cost reductions [10] - The net loss for 2025 was $9.6 million, a substantial improvement from a net loss of $126.6 million in 2024 [10][16] Pipeline Developments - CNTY-813, the lead program for type 1 diabetes, is in IND-enabling studies, with an IND submission expected in Q4 2026 and initial clinical data anticipated in the second half of 2027 [5][6] - CNTY-308, a CD19-targeted CAR-iT cell therapy, is on track to enter clinical trials in 2026, demonstrating promising preclinical results [5][6] - The company expects to release updated preliminary clinical data from the ongoing CARAMEL study in 2026, which has shown early signs of clinical response in autoimmune diseases [6] Corporate Developments - Century Therapeutics appointed two new members to its Board of Directors in December 2025, enhancing its governance structure [10] - The company’s cash position as of December 31, 2025, was $117.1 million, down from $220.1 million in 2024, but sufficient to support operations into Q1 2029 [10][13]

Core Insights - Century Therapeutics is advancing its iPSC-derived cell therapies targeting autoimmune diseases and cancer, with a focus on Type 1 diabetes (T1D) and B-cell-mediated diseases [2][5][6] Business Update - The company announced its lead iPSC-derived beta islet program for T1D, with plans to initiate IND-enabling studies by the end of 2025 and submit an IND as early as 2026 [2][5][6] - CNTY-308 is progressing through IND-enabling studies, aiming for clinical study initiation in 2026 [5][6] - CNTY-101 is continuing in a Phase 1/2 investigator-sponsored trial, with initial clinical data expected in December 2025 [6] Financial Results - As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $132.7 million, down from $220.1 million at the end of 2024, with an estimated cash runway into Q4 2027 [6][10] - R&D expenses for Q3 2025 were $22.5 million, a decrease from $27.2 million in Q3 2024, primarily due to reduced personnel and manufacturing costs [6][10] - G&A expenses were $6.8 million for Q3 2025, down from $8.4 million in Q3 2024, attributed to a gain on lease modification [10] - The net loss for Q3 2025 was $34.4 million, compared to a net loss of $31.2 million for the same period in 2024 [10][13]